Detailed results from pivotal TALAPRO-3 study presented at ASCO 2026 and published in The New England Journal of Medicine ...
Stories by SWNS on MSN
Prostate cancer treatment breakthrough could boost survival rates
A breakthrough in treating an aggressive form of prostate cancer could boost survival rates, according to new research.
Prostate cancer specialists oppose plans to restrict screening to only a few thousand men, research has shown.
Scientists at the world's largest cancer conference have hailed the start of a new drug 'revolution'.
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...
The foundation asked for $6.4 million over four years in Budget 2026 to fund two regional pilots for the early detection ...
The NHS is set to reject a national rollout of a blood test for cancer despite it diagnosing four times as many people with the disease as standard screening.
Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...
The breakthrough at Columbia University lays the groundwork for future clinical studies aimed at developing new treatments.
Research found that the weight-loss medications may reduce the spread of several obesity-related cancers, including lung, ...
NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced results from the final analysis of the Phase 3 PROTEUS study, evaluating apalutamide plus hormone therapy (androgen deprivation therapy, ADT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results